1. Home /
    2. Altai Protocol Library /
  2. New Drug: Mosunetuzumab in patients with relapsed or refractory follicular lymphoma

Altai Protocol Library

1041 protocols and counting

All protocols with references and links

All protocols reviewed by a Medical Oncologist/Hematologist

All protocols in major guidelines included

Ability to create your own protocols

Search Library Posts Search
Altai Protocol Library

New Drug: Mosunetuzumab in patients with relapsed or refractory follicular lymphoma

New Drug: Mosunetuzumab in patients with relapsed or refractory follicular lymphoma
Study:
  • Single-arm, multicenter, phase 2 study
  • Relapsed or refractory to two or more previous lines of treatment
  • Mosunetuzumab q21 days (n=90)
Efficacy:
  • ORR: 80.0% [70·3–87·7; 72 of 90 pts]
  • CR: 60.0% [49·1–70·2; 54 of 90 pts]
  • mPFS: 17·9 mos [10·1– NR]
Safety:
  • Grade 1-2: Cytokine release syndrome (42%); Fatigue (37%)
  • Grade ≥3: Hypophosphataemia (17%); Neutropenia (13%)

Lancet Oncol. 2022 Aug; 23(8):1055-1065.

Budde L.E. et al., Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study

https://doi.org/10.1016/S1470-2045(22)00335-7

Reviewed by Elvin CHALABİYEV, MD on Jan 30, 2023

Altai Chemo Planner

Quickly Prepare Accurate Chemotherapy Orders

Altai Chemo Planner employs Altai Protocol Library that includes over 1000 chemotherapy protocols for both Hematology and Oncology. You can find major guidelines' protocols, parenteral, and oral, in the library. Altai Protocol Library is frequently and regularly updated.

Learn More